Congratulations to our portfolio company CorriXR Therapeutics. They’ve secured a $1 million investment from the State of Delaware through the Delaware Accelerator & Seed Capital Program.
This funding represents more than capital. It’s a powerful endorsement of CorriXR’s mission to transform the treatment of solid tumors through its pioneering CRISPR-based therapeutics. The investment will support the company’s lead program as it advances toward first-in-human clinical trials, scaling its technology, and preparing for regulatory milestones.
We’re proud to see CorriXR continue to grow and grateful to see Delaware backing innovation that brings cutting-edge research closer to real patient impact.
Read more about this milestone:
CorriXR Press Release
CorriXR Post